June 30, 2020 / 1:21 PM / 2 days ago

BRIEF-Alnylam Reports New 12-Month Interim Data From The Envision Phase 3 Study Of Givosiran In Acute Hepatic Porphyria

June 30 (Reuters) - Alnylam Pharmaceuticals Inc:

* ALNYLAM REPORTS NEW 12-MONTH INTERIM DATA FROM THE ENVISION PHASE 3 STUDY OF GIVOSIRAN IN ACUTE HEPATIC PORPHYRIA

* ALNYLAM PHARMACEUTICALS INC - SAFETY PROFILE CONSISTENT WITH THAT OBSERVED IN 6-MONTH DOUBLE-BLIND PERIOD, WITH NO NEW SAFETY FINDINGS

* ALNYLAM PHARMACEUTICALS INC - LONG-TERM GIVOSIRAN DOSING SHOWED SUSTAINED REDUCTION IN ANNUALIZED RATE OF COMPOSITE PORPHYRIA ATTACKS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below